Alzheimer’s and AAMI Reviewed by NeuroPerspective

SAN DIEGO, Sept. 15, 2015 /PRNewswire/ — NI Research has released the September issue of NeuroPerspective, which features a comprehensive review of Alzheimer’s therapeutics.Logo –”Alzheimer’s constitutes the single largest opportunity in the pharma world, but it also presents a daunting legacy of clinical disappointments. To some degree, the neuroscience area has allowed theory to drive the science, instead of the other way around, and as a result, the path to disease-modifying therapies has seen remarkably little headway made, and symptomatic treatments have taken on greater relative importance,” said NeuroPerspective publisher Harry Tracy PhD.”The lack of satisfactory options means that those in the real world treating Alzheimer’s may gratefully add a new drug to the repertoire, so long as they are sure it is reasonably safe and they can say that…

Link to Full Article: Alzheimer’s and AAMI Reviewed by NeuroPerspective

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!